Join the Auvi-Q group to help and get support from people like you.
Auvi-Q News
Monthly News Roundup - August 2024
FDA Clears Pfizer and Moderna 2024-2025 COVID-19 mRNA Vaccines On August 22, the FDA approved the latest COVID-19 mRNA monovalent vaccines from Moderna (Spikevax) and Pfizer / BioNTech (Comirnaty) ...
AAAAI: Nasal Delivery of Epinephrine Safe, Effective for Anaphylaxis
WEDNESDAY, March 6, 2024 – Nasal powder formulations of epinephrine are effective and show superior stability to EpiPens, according to a study presented at the annual meeting of the American Academy...
AAAAI: Nasal Delivery of Epinephrine Safe, Effective for Anaphylaxis
WEDNESDAY, March 6, 2024 – Nasal powder formulations of epinephrine are effective and show superior stability to EpiPens, according to a study presented at the annual meeting of the American Academy...
Allergy Alert: What Could New Guidelines on Anaphylaxis Mean for You?
TUESDAY, Jan. 23, 2024 – If you or someone close to you suffers from severe allergic reactions, you have probably heard there are new recommendations out that offer guidance on the diagnosis,...
FDA Wants More Data on Neffy, First Needle-Free Antidote for Severe Allergic Reactions
WEDNESDAY, Sept. 20, 2023 – In a surprising move, the U.S. Food and Drug Administration (FDA) has opted not to approve a needle-free alternative to the EpiPen for emergency treatment of severe...
FDA Medwatch Alert: Spectrum Laboratory Products, Inc. Issues Voluntary Worldwide Recall of Epinephrine (L-Adrenaline) USP Bulk Active Pharmaceutical Ingredient (API) Due to Discoloration of Product
January 9, 2023 – Spectrum Laboratory Products, Inc. is voluntarily recalling three lots of Epinephrine (L-Adrenaline) USP, a bulk active pharmaceutical ingredient (API) used to manufacture or...
FDA Medwatch Alert: FDA Alerts Patients and Health Care Professionals that Some EpiPen Auto-Injectors May Not Readily Slide Out of Carrier Tube
[11/2/2018] FDA is alerting patients, caregivers and health care professionals that the labels attached to some EpiPen 0.3mg and EpiPen Jr 0.15mg auto-injectors, and the authorized generic versions,...
FDA Approves Kaléo’s Auvi-Q (Epinephrine Injection, USP) 0.1 mg Auto-Injector for Life-Threatening Allergic Reactions in Infants and Small Children
Richmond, VA (November 20, 2017) kaléo, a privately-held pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application ...
FDA Medwatch Alert: Auvi-Q (epinephrine injection, USP): Recall - Potential Inaccurate Dosage Delivery
ISSUE: Sanofi US is voluntarily recalling all Auvi-Q (epinephrine injection, USP). The recall involves all Auvi-Q currently on the market and includes both the 0.15 mg and 0.3 mg strengths for...
Further information
Related condition support groups
Anaphylaxis, Allergic Reactions